EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudie

Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core‐binding factor AML patients in CR2 : A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Yishan Ye iD, Myriam Labopin, Socié Gérard, Ibrahim Yakoub-Agha, Igor Wolfgang Blau, Mahmoud Aljurf, Edouard Forcade, Tobias Gedde-Dahl, David Burns, Jan Vydra, Khalid Halahleh, Rose-Marie Hamladji und 10 weitere

American Journal of Hematology · 2024

DOI: 10.1002/ajh.27342 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Yishan Ye und 21 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation, Siblings, Unrelated Donors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Medical Science and Technology Project of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allogeneic hematopoietic cell transplantation (allo‐HCT) is recommended for core‐binding factor mutated (CBF) AML patients achieving second complete remission (CR2). However, approximately 20% of patients may relapse after transplant and donor preference remains unclear. We compared in this EBMT global multicenter registry‐based analysis the allo‐HCT outcomes using either haploidentical (Haplo), matched siblings donors (MSD), or 10/10 matched unrelated donors (MUD). Data from 865 de novo adult CBF AML patients in CR2 receiving allo‐HCT in 227 EBMT centers from 2010 to 2022 were analyzed, in which 329 MSD, 374 MUD, and 162 Haplo‐HCTs were included. For the entire cohort, 503 (58%) patients were inv(16)/CBFB‐MYH11 and 362 patients (42%) were t (8;21)/RUNX1‐RUNX1T1 AML. On multivariate analysis, Haplo‐HCT was associated with a lower Relapse Incidence (RI) compared to either MSD (hazard ratio [HR] = 0.56, 95% CI 0.32–0.97; p < .05) or MUD (HR = 0.57, 95% CI: 0.33–0.99, p < .05). No significant difference was observed among the 3 types of donors on LFS, OS and GRFS. CBF‐AML with t (8;21) was associated with both higher RI (HR = 1.79, 95% CI 1.3–2.47; p < .01) and higher NRM (HR = 1.58, 95% CI 1.1–2.27; p < .01) than CBF‐AML with inv(16), which led to worse LFS, OS and GRFS. To conclude, for CBF‐AML patients in CR2, Haplo‐HCTs were associated with a lower RI compared to MSD and MUD allo‐HCTs. There was no difference on LFS, OS or GRFS. CBF AML patients with inv(16) had a better progonosis than those with t (8;21) after allo‐HCT in CR2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHematopoietic Stem Cell TransplantationSiblingsUnrelated DonorsRecurrenceHumansMaleFemaleMiddle AgedAdultIncidenceAgedTransplantation, HaploidenticalAdolescentRegistriesCore Binding FactorsYoung AdultRemission InductionAllograftsEurope

Substanzen

Core Binding Factors

Autor:innen und Institutionen

  • Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • EBMT Paris Study Office, Hôpital Saint Antoine 184, Paris Cedex 12, France.
  • Saint-Louis Hospital, BMT Unit, Paris, France.
  • CHU de Lille, Univ de Lille, INSERM U1286, Lille, France.
  • Department of Hematology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
  • King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.

ORCID-Profile: Yishan Ye, Ali Bazarbachi, Lin Li, Norbert Claude Gorin

Förderung

  • National Natural Science Foundation of China
  • Medical Science and Technology Project of Zhejiang Province

Zitieren

APA

Ye, Y., Labopin, M., Gérard, S., Yakoub-Agha, I., Blau, I. W., Aljurf, M., Forcade, E., Gedde-Dahl, T., Burns, D., Vydra, J., Halahleh, K., Hamladji, R. M., Bazarbachi, A., Nagler, A., Brissot, E., Li, L., Luo, Y., Zhao, Y., Ciceri, F., …, & Gorin, N. C. (2024). Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core‐binding factor AML patients in CR2 : A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. American Journal of Hematology. https://doi.org/10.1002/ajh.27342

Vancouver

Ye Y, Labopin M, Gérard S, Yakoub-Agha I, Blau IW, Aljurf M, et al. Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core‐binding factor AML patients in CR2 : A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. American Journal of Hematology. 2024. doi:10.1002/ajh.27342

BibTeX
@article{Ye2024,
  author = {Ye, Yishan and Labopin, Myriam and Gérard, Socié and Yakoub-Agha, Ibrahim and Blau, Igor Wolfgang and Aljurf, Mahmoud and Forcade, Edouard and Gedde-Dahl, Tobias and Burns, David and Vydra, Jan and Halahleh, Khalid and Hamladji, Rose-Marie and Bazarbachi, Ali and Nagler, Arnon and Brissot, Eolia and Li, Lin and Luo, Yi and Zhao, Yanmin and Ciceri, Fabio and Huang, He and Mohty, Mohamad and Gorin, Norbert Claude},
  title = {Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core‐binding factor AML patients in CR2 : A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation},
  journal = {American Journal of Hematology},
  year = {2024},
  doi = {10.1002/ajh.27342}
}
Kostenlos starten →